Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

B.N. Hangalapura, D. Oosterhoff, T. Gupta, J. de Groot, P.G.J.T.B. Wijnands, V.W. van Beusechem, J. den Haan, T. Tuting, A.J.M. van den Eertwegh, D.T. Curiel, R.J. Scheper, T.D. de Gruijl

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)2313-2321
JournalVaccine
Volume29
Issue number12
DOIs
Publication statusPublished - 2011

Cite this